Chicago-based Tempus AI has gained clearance from the U.S. Meals and Drug Administration (FDA) for a brand new synthetic intelligence (AI) algorithm that identifies sufferers who could face a heightened threat of experiencing atrial fibrillation (AFib). The Tempus ECG-AF algorithm evaluates 12-lead electrocardiogram (ECG) outcomes, alerting customers when the affected …
Read More »FDA clears new AI algorithm for 1-year AFib threat
